Zilovertamab vedotin
Product Specifications
Target
Apoptosis|||Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related|||Apoptosis
Bioactivity
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE) . Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6504420-01 0.1 mL
UBC9, NT (SUMO-conjugating Enzyme UBC9, SUMO-protein Ligase, Ubiquitin-conjugating Enzyme E2 I, Ubiquitin-protein Ligase I, Ubiquitin Carrier Protein I, Ubiquitin Carrier Protein 9, p18, UBE2I, UBC9, UBCE9) (MaxLight 750)
Ask
View Details MBS6504420-02 5x 0.1 mL
UBC9, NT (SUMO-conjugating Enzyme UBC9, SUMO-protein Ligase, Ubiquitin-conjugating Enzyme E2 I, Ubiquitin-protein Ligase I, Ubiquitin Carrier Protein I, Ubiquitin Carrier Protein 9, p18, UBE2I, UBC9, UBCE9) (MaxLight 750)
Ask
View Details